2 weeks Ago By Jung So-yeon
Celltrion and Celltrion Pharm are participating side by side at the AACR 2025 (American Association for Cancer Research), the world's largest cancer conference, taking place in Chicago from April 25 to 30, to accelerate their entry into the global oncology drug market. According to Celltrion Group on April 22, Celltrion will make its first oral presentation of preclinical results for its multi-antibody candidate, CT-P72, while Celltrion Pharm will unveil the results of its dual payload antibody-drug conjugate (ADC) technology in a poster format. This simultaneous international debut of the two subsidiaries' key technologies is attracting significant attention from industry stakeholders and investors.
CT-P72, presented by Celltrion, is a next-generation multi-antibody-based therapy co-developed with the U.S. biotech company ABPRO.
It employs a T-cell engager (TCE) approach targeting HER2 (human epidermal growth factor receptor 2), connecting cancer cells and immune cells (T-cells) to induce the immune system to directly eliminate cancer cells. This differentiated approach from existing ADC-based cancer therapies raises expectations for clinical entry and expansion of the pipeline. Meanwhile, Celltrion Pharm's presentation of "CTPH-02" features a dual payload ADC platform technology that combines two cytotoxic drugs with different mechanisms of action into a single antibody.
This approach maximizes anticancer efficacy compared to single payloads and allows for more precise targeted therapy, making it a notable contender in next-generation cancer drug technology. Through this presentation, both companies aim to validate their respective new drug pipelines and platform capabilities while also initiating synergy creation through research and development (R&D) collaboration. Celltrion has set a long-term goal to submit global clinical trial applications (INDs) for a total of 13 new drug candidates, including 9 ADCs and 4 multi-antibodies, by 2028.
The strategy aims to rapidly expand their footprint in the new drug development field based on global development experience accumulated in the antibody biosimilar sector. Last month, Celltrion received IND approval from the FDA for its ADC cancer drug, CT-P70, marking the official start of its clinical development. CT-P70 is designed to target cMET, a cell growth factor that induces tumor growth.
Additionally, Celltrion plans to submit INDs for CT-P71, CT-P73, and CT-P72, which is being unveiled at AACR, within this year. "Celltrion and Celltrion Pharm are establishing themselves as companies with competitive new drugs and platform technologies on the global stage," said an official from Celltrion Group. "We aim to leap into a 'big pharma' status in the global biopharmaceutical market through the development of next-generation cancer therapies.
".
